Section Arrow
Quote
RARE.NASDAQ
- Ultragenyx Pharmaceutical
Quotes are at least 15-min delayed:2026/09/03 11:40 EDT
Regular Hours
Last
 14.6
-11.93 (-44.97%)
Day High 
15 
Prev. Close
26.53 
1-M High
28.5 
Volume 
14.50M 
Bid
14.58
Ask
14.62
Day Low
13.81 
Open
14 
1-M Low
24.01 
Market Cap 
2.62B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 25.92 
20-SMA 26.11 
50-SMA 28.27 
52-W High 39.8899 
52-W Low 18.29 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.83/0.81
Enterprise Value
2.64B
Balance Sheet
Book Value Per Share
-2.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
673.00M
Operating Revenue Per Share
4.16
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RAREUltragenyx Pharmaceutical14.53-12-45.23%-- 
ATAIAtaiBeckley Inc7.415+0.065+0.88%-- 
SMMTSummit Therapeutics16.37+1.77+12.12%-- 
RXRXRecursion Pharmaceuticals3.3609-0.0191-0.57%-- 
MRNAModerna144.76-6.05-4.01%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitatinggenetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated fromNorth America.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.